NuRAN's Form 40-F became effective June 26, 2026, clearing a major US regulatory hurdle and enabling MJDS-based SEC reporting. Nasdaq listing remains under review with no assurance of approval; success could broaden the investor base. Trading on CSE, OTC, and FSE continues, with potential liquidity benefits contingent on Nasdaq decision.
Regulatory clearance for US registration and possible Nasdaq uplisting can boost liquidity and broaden the investor base, a positive read-through for NUR; however, timing and listing approval remain uncertain.
Near-term upside potential exists if Nasdaq approval occurs within 6-12 months, driving US liquidity for NUR.
Category: Corporate Developments. The release outlines regulatory milestones affecting NuRAN's US listing plan and capital-markets strategy rather than operating results.